Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial-Reference-Cited by-同舟云学术

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Published:2021-08 Issue:8 Volume:9 Page:897-908
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Wallis Robert S,Ginindza Sibuse,Beattie Trevor,Arjun Nishanee,Likoti Morongwe,Edward Vinodh A,Rassool Mohammed,Ahmed Khatija,Fielding Katherine,Ahidjo Bintou A,Vangu Mboyo D T,Churchyard Gavin

Funder

Bill and Melinda Gates Foundation

South African Medical Research Council

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference40 articles.

1. Chronic obstructive airways disease following treated pulmonary tuberculosis;Willcox;Respir Med,1989

2. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study;Duong;Lancet Glob Health,2019

3. Advancing host-directed therapy for tuberculosis;Wallis;Nat Rev Immunol,2015

4. Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis;Subbian;Front Immunol,2016

5. Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model;Subbian;EBioMedicine,2016

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing against antibiotic resistant bacterial pathogens;European Journal of Medicinal Chemistry;2024-12

2. An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives;Current Pharmaceutical Biotechnology;2024-10

3. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis;NEJM Evidence;2024-08-27

4. Leveraging insights from cancer to improve tuberculosis therapy;Trends in Molecular Medicine;2024-08

5. Advances in an In Vitro Tuberculosis Infection Model Using Human Lung Organoids for Host-Directed Therapies;PLOS Pathogens;2024-07-25